Menu Search
Equities

Ginkgo Bioworks Holdings Inc

9L4:BER

Ginkgo Bioworks Holdings Inc

Actions
  • Price (EUR)2.52
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 25 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

  • Revenue in USD (TTM)208.70m
  • Net income in USD-853.81m
  • Incorporated2021
  • Employees1.22k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		DNA:NYQ since
announced		Transaction
value
Proof Diagnostics IncDeal completed28 Feb 202428 Feb 2024Deal completed-45.16%--
Patch Biosciences IncDeal completed26 Feb 202426 Feb 2024Deal completed-36.44%--
Reverie Labs IncDeal completed23 Feb 202423 Feb 2024Deal completed-36.44%--
Data delayed at least 15 minutes, as of May 17 2024 00:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.